Literature DB >> 6318981

Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma.

K Jimbow, Y Miyake, K Homma, K Yasuda, Y Izumi, A Tsutsumi, S Ito.   

Abstract

This study elucidates the nature of melanogenesis in B16 and Harding-Passey (HP) mouse melanomas producing melanin and melanosomes of different color and fine structure, i.e., brown-black eumelanosome-like B16 granules and reddish brown pheomelanosome-like HP granules, and compares them with "typical" 3,4-dihydroxyphenylalanine (DOPA) and sepia eumelanins and sepia eumelanosomes. The melanin content of B16 melanosomes was more than three times higher than that of HP melanosomes. The content of free and protein-bound DOPA and 5-S-cysteinyldopa varied greatly in B16, HP, and sepia melanosomes and was unrelated to melanin content. Chemical analysis of the eumelanin: pheomelanin ratio in melanosomes and elemental analysis of isolated melanin showed that B16 and HP melanins are primarily eumelanic, with a higher ratio of pheomelanic component in HP melanin. The spectra of electron spin resonance and IR and X-ray small-angle scattering of B16 and HP melanins were basically similar to those of sepia and DOPA melanins. B16, HP, and DOPA melanins were dissolved in aqueous NH3, while sepia melanin was dissolved to a far lesser extent. It was concluded that both B16 and HP melanomas are primarily involved in eumelanogenesis, although the fine structure of their melanosomes is entirely different, and that the marked color difference in the two melanosomes is related to a difference in the absolute content of eumelanin, the presence of a small amount of pheomelanin, and the mode of chemical bindings of melanin to structural proteins. In contrast to normal skin and hair, melanosome morphogenesis may not directly correspond to melanogenesis type in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6318981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Is there any difference in the photobiological properties of melanins isolated from human blue and brown eyes?

Authors:  I A Menon; P K Basu; S Persad; M Avaria; C C Felix; B Kalyanaraman
Journal:  Br J Ophthalmol       Date:  1987-07       Impact factor: 4.638

2.  Melanin-targeted preclinical PET imaging of melanoma metastasis.

Authors:  Gang Ren; Zheng Miao; Hongguang Liu; Lei Jiang; Naengnoi Limpa-Amara; Ashfaq Mahmood; Sanjiv S Gambhir; Zhen Cheng
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

3.  Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect.

Authors:  S Miura; T Ueda; K Jimbow; S Ito; K Fujita
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

4.  Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Authors:  Andrzej Slominski; Blazej Zbytek; Radomir Slominski
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

5.  Quantification of melanin and iron content in uveal malignant melanomas and correlation with magnetic resonance image.

Authors:  J D Ferris; P A Bloom; P R Goddard; C Collins
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

Review 6.  The natural history of a family of transplantable melanomas in hamsters.

Authors:  A Bomirski; A Słominski; J Bigda
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

7.  Imaging microscopic pigment chemistry in conjunctival melanocytic lesions using pump-probe laser microscopy.

Authors:  Jesse W Wilson; Lejla Vajzovic; Francisco E Robles; Thomas J Cummings; Prithvi Mruthyunjaya; Warren S Warren
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-21       Impact factor: 4.799

8.  A novel aliphatic 18F-labeled probe for PET imaging of melanoma.

Authors:  Hongguang Liu; Shuanglong Liu; Zheng Miao; Han Jiang; Zixin Deng; Xuechuan Hong; Zhen Cheng
Journal:  Mol Pharm       Date:  2013-08-22       Impact factor: 4.939

9.  Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Authors:  Kowichi Jimbow; Yasue Ishii-Osai; Shosuke Ito; Yasuaki Tamura; Akira Ito; Akihiro Yoneta; Takafumi Kamiya; Toshiharu Yamashita; Hiroyuki Honda; Kazumasa Wakamatsu; Katsutoshi Murase; Satoshi Nohara; Eiichi Nakayama; Takeo Hasegawa; Itsuo Yamamoto; Takeshi Kobayashi
Journal:  J Skin Cancer       Date:  2013-02-21

10.  Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.

Authors:  Tomoaki Takada; Toshiharu Yamashita; Makito Sato; Akiko Sato; Ichiro Ono; Yasuaki Tamura; Noriyuki Sato; Atsushi Miyamoto; Akira Ito; Hiroyuki Honda; Kazumasa Wakamatsu; Shosuke Ito; Kowichi Jimbow
Journal:  J Biomed Biotechnol       Date:  2009-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.